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Urinary endotrophin predicts 
disease progression in patients with 
chronic kidney disease
Daniel Guldager Kring Rasmussen  1,2, Anthony Fenton3,4, Mark Jesky3,4, Charles Ferro3,4, 
Peter Boor  5,6, Martin Tepel2,7, Morten Asser Karsdal1, Federica Genovese1 & Paul Cockwell3,4
Renal fibrosis is the central pathogenic process in progression of chronic kidney disease (CKD). Collagen 
type VI (COL VI) is upregulated in renal fibrosis. Endotrophin is released from COL VI and promotes 
pleiotropic pro-fibrotic effects. Kidney disease severity varies considerably and accurate information 
regarding CKD progression may improve clinical decisions. We tested the hypothesis that urinary 
endotrophin derived during COL VI deposition in fibrotic human kidneys is a marker for progression 
of CKD in the Renal Impairment in Secondary Care (RIISC) cohort, a prospective observational 
study of 499 CKD patients. Endotrophin localised to areas of increased COL VI deposition in fibrotic 
kidneys but was not present in histologically normal kidneys. The third and fourth quartiles of urinary 
endotrophin:creatinine ratio (ECR) were independently associated with one-year disease progression 
after adjustment for traditional risk factors (OR (95%CI) 3.68 (1.06–12.83) and 8.65 (2.46–30.49), 
respectively). Addition of ECR quartiles to the model for disease progression increased prediction 
as seen by an increase in category-free net reclassification improvement (0.45, 95% CI 0.16–0.74, 
p = 0.002) and integrated discrimination improvement (0.04, 95% CI 0.02–0.06, p < 0.001). ECR was 
associated with development of end-stage renal disease (ESRD). It is concluded that ECR predicts 
disease progression of CKD patients.
Chronic kidney disease (CKD) is associated with end-stage renal disease (ESRD) and increased risk of mortal-
ity1,2. Progressive fibrosis is the major pathophysiological process in CKD and collagens are the main structural 
components of the fibrotic tissue1,3,4. As collagen formation and fibrosis progression are closely linked, assessment 
of active collagen formation may identify CKD patients at high risk of progression, including those who have the 
greatest potential for targeted anti-fibrotic therapies5,6.
COL VI is an important structural collagen positioned at the interface between the interstitial matrix and the 
glomerular basement membrane. It forms an intricate meshwork of microfilaments with a physiological role in 
maintaining structure and function, controlling the organization of the matrix and cell orientation7. Increased 
deposition in the kidneys has been reported in animal models of kidney disease and in CKD in humans8,9.
Recent seminal studies have shown that collagens can also interact with both their immediate surroundings 
and distant sites through the release of fragments with stimulating and signalling activity, termed matrikines6,10. 
During production of COL VI, the pro-peptide of the alpha-3 chain is released, containing endotrophin11,12. Due 
to sequence overlap in endotrophin and the pro-peptide of COL VI, endotrophin may be a potential surrogate 
biomarker for COL VI formation. Endotrophin also promotes biological effects, such as acting as a chemoattract-
ant on macrophages, increasing TGFβ signalling, and epithelial-mesenchymal transition13. Additional systemic 
effects include adipose tissue fibrosis and metabolic dysfunction13. We have recently shown that increased serum 
endotrophin is independently associated with mortality in CKD patients14 and elevated in renal transplant recip-
ients with chronic rejection15. However, the role of urinary endotrophin in the pathophysiology of CKD has not 
been elucidated. We tested the hypothesis that endotrophin is produced in fibrotic human kidneys and that uri-
nary endotrophin is a marker for progression of CKD in a prospective observational study of 499 CKD patients.
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To address this, we analysed the localization of endotrophin and COL VI in situ and studied the association 
of urinary endotrophin:creatinine ratio (ECR) with one-year disease progression and development of ESRD in a 
large prospective study of patients with high-risk CKD.
Results
Presence of endotrophin in fibrotic kidney. Masson’s trichrome staining in the non-fibrotic kidneys 
revealed only a focal and mild positivity (Fig. 1A), whereas in the fibrotic kidneys intense collagen staining was 
observed (Fig. 1B). Staining of COL VI showed low expression in the interstitium and surrounding larger blood 
vessels in the non-fibrotic kidney (Fig. 1C). In accordance with previous studies8,9, the fibrotic kidneys revealed a 
noticeable staining of COL VI indicating a prominent deposition in fibrotic areas (Fig. 1D). Staining for endotro-
phin showed no signal in the non-fibrotic kidneys suggesting very low COL VI turnover (Fig. 1E). In fibrotic 
kidneys, a prominent staining for endotrophin was observed, in areas that co-localized with high COL VI staining 
(Fig. 1F).
Baseline characteristics of study subjects. The cohort was 61.5% male, median age was 64 years (IQR 
50–76), and ethnicity was 72.2% white, 18.0% south-Asian, 8.8% Black, and 1.0% other. The primary renal diag-
nosis was ischaemia/hypertension in 26.1%, diabetic kidney disease in 9.6%, glomerulonephritis in 16.6%, poly-
cystic kidney disease in 5.8%, and of other or uncertain aetiology in 41.9%. Median (IQR) estimated glomerular 
Figure 1. Histological and immunohistological assessment of tissue sections from control and fibrotic kidneys. 
The left (A, C, E and A’, C’, E’) and right panel (B, D, F and B’, D’, F’) show representative sections from two 
paraffin-embedded biopsies of a non-fibrotic kidney and fibrotic kidney, respectively. (A,B) Whereas Masson’s 
trichrome stain led to a very mild and only focal positivity in the control kidneys, a more intense staining, was 
observed in the fibrotic kidney. (C) Immunohistochemistry of the non-fibrotic control kidneys using anti-COL 
VI antibody (αCol6) revealed some staining in the interstitium and surrounding larger blood vessels. (D) The 
fibrotic kidneys showed noticeable, αCol6 staining in the fibrotic areas, indicating a prominent upregulation 
of COL VI in fibrosis. (E) Immunohistochemistry of the non-fibrotic kidneys using the anti-Endotrophin 
antibody (PRO-C6), did not reveal any staining. (F) The fibrotic kidney section showed a clear Endotrophin 
signal within the fibrotic foci, particularly those with high COL VI content (1D’ and F’). The subfigures labelled 
with a mark (e.g. A’) are magnifications of the areas outlined with a square. In the fibrotic kidney, the square 
outlines the same area in subfigures (B, D and F). The scale bars are 250 µm.
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filtration rate (eGFR) was 27 (20–35) mL/min/1.73 m2, median (IQR) for urinary albumin:creatinine excretion 
ratio (ACR) was 32 (6–128) mg/mmol, and median (IQR) ECR was 0.7 (0.3–2.2) ng/µmol.
Baseline variables for the study participants stratified by ECR quartile, are presented in Table 1. Subjects in 
the higher quartiles were older, had higher probability of having diabetes as the primary renal diagnosis and as 
comorbidity, had lower probability of having glomerulonephritis, and in general had a higher level of comorbid-
ity (age-adjusted Charlson’s Comorbidity Index (CCI) score above 5). Also, in subjects of the highest quartiles, 
a higher systolic blood pressure, mean arterial blood pressure (MAP), pulse pressure (PP), serum creatinine, 
cystatin C, ACR and lower kidney function was observed. None of the other variables were significantly different 
between the groups.
ECR correlates with eGFR, one-year relative change in eGFR and ACR. As eGFR and ACR were 
respectively lower and higher in the higher ECR quartiles, we performed correlation analysis between ECR and 
eGFR, one-year relative change in eGFR and ACR (Fig. 2). As log-transformation did not lead to a Gaussian 
distribution of ECR, we performed Spearman rank correlation analysis. ECR had a moderate, inverse correlation 
with baseline eGFR (rho = −0.58, p < 0.0001, Fig. 2A). Out of the 499 patients, 381 (76.4%) had paired eGFR 
data available at 0 and 12 months and the one-year relative change in kidney function was calculated. ECR had 
an inverse, weak correlation with one-year relative change in eGFR (rho = −0.25, p < 0.0001; Fig. 2B) and a weak 
correlation with ACR (rho = 0.30, p < 0.0001; Fig. 2C).
Patient number ECR (IQR)
All ECR Quartile
P value(n = 499) (0.3–2.2) 1 (n = 125) (0.1–0.2) 2 (n = 126) (0.3–0.5) 3 (n = 123) (0.9–1.7) 4 (n = 125) (3.6–8.8)
Age (years) 64 (50–76) 60 (49–72) 65 (50–78) 66 (52–78) 66 (54–76) 0.02
Gender (male) 307 (61.5) 79 (63.2) 71 (56.3) 79 (64.2) 78 (62.4) 0.57
Ethnicity
   White 360 (72.2) 97 (77.6) 95 (75.4) 85 (69.1) 83 (66.4) 0.16
   Black 44 (8.8) 13 (10.4) 11 (8.7) 13 (10.6) 7 (5.6) 0.48
   South Asian 90 (18.0) 14 (11.2) 19 (15.8) 23 (18.7) 34 (27.2) 0.008
   Other 5 (1.0) 1 (0.8) 1 (0.8) 2 (1.6) 1 (0.8) 0.89
Primary renal diagnosis
   Ischaemia/hypertension 130 (26.1) 30 (24.0) 35 (27.8) 31 (25.2) 34 (27.2) 0.9
   Diabetes mellitus 48 (9.6) 11 (8.8) 4 (3.2) 11 (8.9) 22 (17.6) 0.002
   Glomerulonephritis 83 (16.6) 34 (27.2) 23 (18.3) 18 (14.6) 8 (6.4) 0.0002
   Polycystic kidney disease 29 (5.8) 6 (4.8) 10 (7.9) 10 (8.1) 3 (2.4) 0.16
   Other/Unknown 209 (41.9) 44 (35.2) 54 (42.8) 53 (43.2) 58 (46.4) 0.33
Co-morbidities
   Malignancy 72 (14.4) 15 (12.0) 19 (12.7) 17 (13.8) 21 (16.8) 0.74
   Diabetes mellitus 183 (36.7) 39 (31.2) 37 (29.4) 47 (38.2) 61 (48.8) 0.006
   COPD 60 (12.0) 16 (12.8) 22 (17.5) 11 (8.9) 11 (8.8) 0.12
   Cerebrovascular disease 54 (10.8) 15 (12.0) 13 (10.3) 11 (8.9) 15 (12.0) 0.84
   Ischaemic heart disease 112 (22.4) 30 (24.0) 30 (23.8) 22 (17.9) 30 (24.0) 0.58
   Peripheral vascular disease 51 (10.2) 12 (9.6) 11 (8.7) 16 (13.0) 12 (9.6) 0.69
Age-adjusted CCI (score ≥ 5) 278 (55.7) 52 (41.6) 73 (57.9) 72 (58.5) 81 (64.8) 0.0004
Smoking (Current) 67 (13.4) 21 (16.8) 20 (15.9) 15 (12.2) 11 (8.8) 0.31
Socioeconomic status 29.0 (16.5–45.1) 28.7 (16.3–44.1) 25.5 (15.3–45.1) 33 (19.3–44.6) 27 (17–47) 0.66
BMI (kg/m2) 29 (25–33) 30 (26–33) 29 (25–32) 28 (25–33) 28 (24–35) 0.53
Systolic BP (mmHg) 124 (114–139) 119 (109–129) 123 (113–140) 126 (116–142) 127 (116–148) <0.0001
Diastolic BP (mmHg) 74 (67–83) 74 (66–82) 75 (67–81) 74 (67–84) 75 (68–83) 0.92
Mean arterial pressure (mmHg) 91 (84-99) 90 (83–96) 91 (84–98) 94 (84–101) 94 (86–100) 0.02
Pulse pressure (mmHg) 48 (37–63) 42 (34–53) 49 (36–66) 51 (39–65) 51 (40–68) <0.0001
Serum creatinine (μmol/L) 203 (161–259) 158 (137–197) 189 (149-225) 216 (181–260) 270 (222-345) <0.0001
Cystatin C (mg/L) 2.5 (2.0–3.1) 1.9 (1.6–2.3) 2.3 (1.8-2.8) 2.5 (2.0–3.0) 3.1 (2.6–3.7) <0.0001
eGFR (mL/min/1.73m2) 27 (20–35) 36 (28–46) 28 (23–38) 25 (20–29) 18 (14–24) <0.0001
ACR (mg/mmol) 32 (6–128) 10 (2–76) 23 (6–129) 47 (9–163) 77 (15–184) <0.0001
CRP (mg/L) 3.1 (1.5–6.8) 2.8 (1.1–6.5) 3.6 (1.5–8.0) 2.7 (1.5–5.0) 3.9 (1.9–8.1) 0.18
Table 1. Clinical characteristics of study subjects stratified by quartiles of ECR. Categorical variables are 
expressed as number (%), and continuous variables as median (IQR). Below the quartile headers the IQR for 
ECR has been inserted (ng/µmol creatinine). COPD, chronic obstructive pulmonary disease; CCI, Charlson’s 
comorbidity index; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; ACR, 
albumin:creatinine ratio; CRP, C-reactive protein; ECR, Endotrophin:creatinine ratio.
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ECR is associated with one-year disease progression. Forty six (11.1%) of 416 patients alive and with 
one year follow-up data had progressed. Relative to the lowest quartile, the third and fourth quartiles of ECR had 
odds ratios (ORs) for progression of 5.48 (Q3; 95% CI 1.51–19.83, p = 0.01), and 15.19 (Q4; 95% CI 4.46–51.76, 
p < 0.0001), respectively (Fig. 3).
Next we investigated whether the association of the third and fourth quartile of ECR with one-year disease 
progression was independent of traditional risk factors of disease progression, and thus adjusted for age, gender, 
eGFR and ACR16. Both Q3 and Q4 were independently associated with one-year disease progression with ORs 
of 3.68 (95% CI 1.06–12.83, p = 0.04) and 8.65 (95% CI 2.46–30.49, p = 0.001), respectively. The analysis was also 
performed with tertiles of ECR. Relative to the lowest tertile, the second and third tertile had ORs of 4.03 (95% 
CI 1.08–14.97, p = 0.04) and 17.19 (95% CI 5.13–57.60, p < 0.0001), respectively. Adjusted for age, gender, eGFR 
Figure 2. ECR correlates with eGFR, one-year relative change in eGFR and albuminuria. Correlation analysis 
between ECR and (A) baseline eGFR, (B) one-year relative change in eGFR, and (C) ACR are presented. Due 
to non-normal distribution of data, spearman’s rank correlation analysis was performed. For visualization, 
all values, except relative change in eGFR, were log-transformed. In each subfigure, spearman’s rho and 
significance level is shown.
Figure 3. The association of ECR quartiles with one-year disease progression. Odds ratios with 95% CI were 
plotted for quartiles (Q) of ECR.
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and ACR only the third tertile of ECR remained independently associated with one-year disease progression (OR 
3.02, 95% CI 1.31–6.95, p = 0.009).
To investigate whether addition of ECR quartiles to the model of traditional risk factors, reported by Tangri 
et al.16, improved prediction of one-year disease progression, we performed category-free net reclassification 
index (cfNRI) and integrated discrimination improvement (IDI). The addition of ECR quartiles to the model 
increased prediction as seen by a significant increase in category-free net reclassification improvement (0.45, 95% 
CI 0.16–0.74, p = 0.002) and integrated discriminatory improvement (0.04, 95% CI 0.02–0.06, p < 0.001).
To further dissect the effect of other variables on the association of ECR with one-year disease progression, 
we adjusted ECR for eGFR and ACR alone and in combination, and for all variables that differed significantly 
between ECR quartiles including gender16 (Table 2). Adjustment of ECR for either eGFR or ACR did not mark-
edly affect the association with one-year disease progression (all p < 0.001). Adjustment for eGFR and ACR in 
combination lead to a reduction in the association of ECR with one-year disease progression, but the association 
remained significant (per increase in 1 SD; OR 1.42, 95% CI 1.04–1.93, p = 0.03). Even after adjusting for all var-
iables that differed significantly between ECR quartiles including gender16, the association remained significant 
(per increase in 1 SD; OR 1.63, 95% CI 1.15–2.32, p = 0.007).
Association of ECR with Development of ESRD. One hundred and twenty-five (25.1%) of 499 patients 
developed ESRD during the follow-up period. ECR level when analysed as a continuous variable (Table 2) or by 
quartiles (Fig. 4) was significantly associated with the development of ESRD. Patients in Q2, Q3 and Q4 of ECR 
had hazard ratios (HR) of 2.41 (95% CI 1.19–4.90, p = 0.015), 3.92 (95% CI 1.99–7.73, p = 0.0001) and 7.20 (95% 
CI 3.76–13.78, p < 0.0001), respectively, relative to the lowest quartile. The number and percentage of patients 
advancing to ESRD in each ECR quartile were 11 (8.8%, Q1), 25 (19.8%, Q2), 35 (28.5%, Q3), and 54 (43.2%, Q4) 
(Log-rank χ2 = 55.3, p < 0.0001).
As was done for one-year disease progression, we investigated the effect of other variables on the association 
of ECR with development of ESRD. We adjusted ECR for eGFR and ACR alone and in combination, and for all 
variables that differed significantly between ECR quartiles, and gender16 (Table 2). Adjustment for eGFR mark-
edly reduced the association of ECR with development of ESRD, but the association still remained significant (per 
increase in 1 SD; HR 1.15, 95% CI 1.00–1.31, p = 0.04). Adjustment for ACR revealed an independent association 
of ECR with development of ESRD (per increase in 1 SD; HR 1.30, 95% CI 1.16–1.00, p < 0.0001). When ECR was 
adjusted for eGFR and ACR in combination, the association with development of ESRD was lost. When ECR was 
adjusted for all variables that differed significantly between ECR quartiles and gender, ECR lost its association 
with the development of ESRD (per increase in 1 SD; HR 0.98, 95% CI 0.83–1.16, p = 0.82)(Table 2).
Discussion
In the present study we tested nonfibrotic and fibrotic kidney biopsies for the presence of endotrophin, and 
measured levels of ECR in samples from patients with high-risk CKD. To our knowledge, this is the first study 
that studies the presence of endotrophin in biopsies, and investigates the prognostic potential of ECR in CKD. 
The main finding was that ECR was associated with one-year disease progression independent of traditional risk 
factors. We also show that addition of ECR quartiles to a model of traditional risk factors significantly increased 
discrimination of events and nonevents for one-year disease progression. Our findings also indicate that endotro-
phin is mainly found in the interstitial matrix in fibrotic kidneys, and localizes to areas of high COL VI expres-
sion. Together our data indicate that endotrophin is produced in fibrotic kidneys and that ECR may reflect disease 
activity in CKD patients.
Model
One-year disease progression ESRD
ORa (95% CI) P-value HRa (95% CI) P-value
Model a 1.55 (1.20–2.02) 0.0009 1.15 (1.00–1.31) 0.04
Model b 1.80 (1.37–2.35) <0.0001 1.30 (1.16–1.00) <0.0001
Model c 1.42 (1.04–1.93) 0.03 0.95 (0.81–1.11) 0.51
Model d 1.63 (1.15–2.32) 0.007 0.98 (0.83–1.16) 0.82
Table 2. Association of ECR with one-year disease progression and development of ESRD. Data are odds 
ratio (OR) or hazard ratio (HR) with 95% CI as specified. One-year disease progression was defined as either 
a decline of eGFR of more than 30% or development of ESRD within one year. Urinary ECR was adjusted 
in four different models: Model a) ECR adjusted for eGFR; Model b) ECR adjusted for ACR; Model c) ECR 
adjusted for eGFR and ACR; and Model d) ECR adjusted for all variables with a univariable association with 
ECR (p < 0.1) and gender16. The variables included in the latter model (“Model d”) included age, gender, 
ethnicity, primary renal diagnosis, diabetes mellitus as comorbidity, age-adjusted CCI (score ≥ 5), PP, eGFR, 
and ACR. Due to missing data for some variables used for adjustment, the fully adjusted model only included 
406 out of 416 patients (98%) with data available for one-year disease progression and 484 out of 499 patients 
(97%) for development of ESRD. Logistic regression analysis was used to analyze the association to one-year 
disease progression, and Cox proportional hazard regression analysis was used to analyze the association 
to development of ESRD. ECR, endotrophin:creatinine ratio; CCI, Charlson’s comorbidity index; PP, pulse 
pressure; eGFR, estimated glomerular filtration rate; ACR, albumin creatinine ratio. aper increase in one 
standard deviation (1 SD) of ECR.
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Renal fibrosis is a hallmark of CKD progression1,3. Collagen is the major constituent of fibrotic lesions and 
consists of multiple types. The major focus to date on collagen in fibrosis has been on collagen type I and type 
III4. However, there is now an increasing interest in the role of COL VI across different organs. Endotrophin is 
generated by the cleavage of the alpha-3 chain of COL VI11,12. Due to sequence overlap in endotrophin and the 
pro-peptide of COL VI, endotrophin may be a potential surrogate biomarker for COL VI formation. Endotrophin 
is a matrikine with multiple pleiotropic effects including the potential to amplify fibrotic processes13. However, 
there have been no studies to date investigating the presence of endotrophin in fibrotic kidneys and the associa-
tion of urinary levels of endotrophin with disease progression in CKD patients.
In normal kidney COL VI co-localised to areas with collagen matrix, as identified by Masson’s trichome, in 
a distribution consistent with that previously described17. Endotrophin is not a component of the steady-state 
COL VI molecule but is released during deposition in the extracellular matrix11. Consistent with this there was 
no detectable endotrophin by immunohistochemistry in histologically normal kidney, indicating that any new 
production of endotrophin in this setting was below the detection threshold for the antibody. However, in estab-
lished fibrosis there was considerable expression of COL VI and this co-localised with prominent expression of 
endotrophin. This suggests that COL VI is actively produced in the fibrotic foci and thus the biologically active 
matrikine endotrophin is also produced.
We utilised a prospective cohort of patients with progressive CKD to explore the association of ECR with one-year 
disease progression and development of ESRD. We found a significant negative correlation between urinary ECR and 
kidney function and between ECR and one-year relative change in kidney function. Urinary ECR levels were inde-
pendently associated with an increased risk of one-year disease progression, and the third and fourth quartiles of ECR 
remained independently associated with the rate of progression after adjustment for the traditional risk factors age, 
gender, eGFR and ACR16. ECR as a continuous variable also remained significantly associated with one-year disease 
progression, even when fully adjusted for potential confounders, including the traditional risk factors16.
When looking at the univariable association between ECR and development of ESRD a striking prognostic ability 
was observed, even after adjustment of ECR by eGFR and ACR alone. The adjustment for eGFR reduced the risk, but 
the association of ECR to development of ESRD was still significant indicating that there is an association independent 
of kidney function. However, when adjusted for eGFR and ACR in combination and adjusted for all potential con-
founders and gender, ECR lost its ability to predict development of ESRD. An explanation for the marked impact of 
eGFR on ECR could be that ECR is a measure of COL VI formation, and therefore may reflect renal fibrosis. As renal 
fibrosis drives the loss of kidney function1,3, eGFR may be part of the pathway which is driven by endotrophin and the 
exacerbated COL VI deposition. Adjusting for eGFR might be adjusting for the same pathway as endotrophin thus 
attenuating the association of ECR with development of ESRD. It is therefore interesting that ECR is independently 
associated with one-year disease progression, as this might indicate that ECR is associated with disease activity and 
thus rate of progression. In the cohort, all patients were designated as having high-risk CKD to ensure that there was a 
substantial amount of patients with a rapid disease progression. All patients therefore had advanced CKD, and thus a 
relatively low eGFR. A future study testing the prognostic ability of ECR in a cohort of patients with mild CKD should 
be conducted to verify whether ECR is associated with disease progression independent of kidney function.
An interesting finding was that albuminuria, as assessed by ACR, did not affect the association of ECR with 
either one-year disease progression or development of ESRD. The presence of endotrophin in urine is therefore 
not likely to be solely due to an increased filtration of proteins into the urine through the glomerular basement 
membrane, and might reflect a release of endotrophin from the fibrotic renal extracellular matrix.
Figure 4. Cumulative Kaplan-Meier plot showing development of ESRD by ECR quartile. A table including 
the number of patients at risk by time has been inserted below the Kaplan-Meier curve. Log-rank significance is 
inserted in the figure. Q = quartiles.
www.nature.com/scientificreports/
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Patients with a primary renal diagnosis of diabetes presented higher ECR levels. A link between type 2 dia-
betes mellitus and endotrophin was previously established by our group18. In this study, levels of serum endotro-
phin predicted which patients could benefit from insulin-sensitising treatment as assessed by lowering of blood 
glucose18. This study suggested that endotrophin may be able to isolate a subgroup of diabetic patients with high 
disease activity. As diabetes is the main cause of CKD, and COL VI is upregulated in kidneys of diabetic patients8, 
our findings add to the hypothesis that high endotrophin levels reflects disease activity favouring progression of 
disease.
Patients with glomerulonephritis had lower levels of ECR than diabetic patients. However, patients with dia-
betes as a primary renal diagnosis had a lower eGFR than patients with glomerulonephritis (data not shown). As 
we showed a negative correlation between eGFR and ECR levels, the discrepancy might be explained by a more 
advanced disease stage of the diabetic patients, than those with glomerulonephritis in the cohort.
Whilst we identify an association between endotrophin and renal outcomes, it is not known whether endotro-
phin is causally linked to progression of renal disease. Also, even though COL VI is upregulated in pathologies 
affecting the kidneys8,9, endotrophin may also increase in comorbidities present in many patients with kidney 
disease. In animal studies, COL VI was upregulated in diabetic rats with hypertension and cardiac fibrosis19 and 
in rats with myocardial infarction20. As mice with COL VI alpha-1 chain deficiency had less cardiac damage fol-
lowing myocardial infarction compared to controls, this might suggest that COL VI is involved in an abnormal 
wound-healing21. The same trend was seen in humans where COL VI was upregulated in atherosclerotic lesions22, 
and in hypertrophic cardiomyopathy where COL VI levels correlated with cardiac dysfunction23. One possible 
explanation for the hazardous nature of COL VI was seen in in vitro experiments where plating of cardiac fibro-
blasts on COL VI induced myofibroblast differentiation20. This might also be seen in vivo, where COL VI was 
upregulated and coincided with increased myofibroblast content in a model of myocardial infarction in rats20. 
As type I and III collagen increase proliferation of cardiac fibroblasts in vitro, the combined increase of type I, 
III, and VI collagen in fibrosis could form a matrix which sustains a vicious fibrotic cycle through proliferation 
and differentiation of fibroblasts20. Overall the findings suggest that COL VI is not only a consequence of fibrotic 
events, but that its presence and post-translational modifications could also drive pathology through the release 
of endotrophin24.
We have previously shown that high levels of serum endotrophin were independently associated with mortal-
ity14. In the current study there was no association with mortality for ECR as a continuous variable or as quartiles, 
and the study only focused on endpoints related to the kidneys (i.e. one-year disease progression and ESRD). The 
analysis on serum endotrophin did not focus on one-year disease progression14, but post-hoc analysis showed 
that the fourth quartile of serum endotrophin was lowly, but significantly associated with one-year disease pro-
gression after adjustment for the same traditional risk factors that were used in the current study. However, the 
association of ECR with one-year disease progression in the current study was more prominent and both the 
third and the fourth quartiles of ECR were independently associated with it. This may indicate that endotrophin 
in urine reflects the pathological changes taking place in the kidney, whereas the serum levels are influenced by 
systemic changes due to the disease. This could also explain the marked difference when analysing serum and 
urine levels of endotrophin in respect to all-cause mortality.
The strengths of this study are that endotrophin was shown in situ in human renal fibrosis and was evaluated 
in a large prospective cohort of high-risk CKD that incorporates multiple risk factors for the clinical end-points 
enabling robust analyses.
The limitations of the study include it being a single-centre cohort, and our reporting of an association of 
endotrophin and clinical outcomes with no supporting mechanistic data. However this study does identify ECR 
as a strong candidate molecule for evaluation in a stratified medicine model of CKD progression. There is an 
urgent need for the development of clinical trial models where early changes in pathology in response to ther-
apy can stratify patients for clinical benefit. We propose that endotrophin should be evaluated as a candidate 
molecule for this role in CKD. This is supported by our findings, where the highest two quartiles of ECR were 
independently associated with one-year disease progression, irrespective of traditional risk factors including age, 
gender, eGFR and ACR. As fast progressors are believed to be more likely to respond to therapy, stratification by 
ECR is highly interesting as it, due to sequence overlap with the pro-peptide, might reflect both COL VI forma-
tion and levels of matrikine with potential deleterious effects.
In conclusion, endotrophin is present in situ in human renal fibrosis at sites of COL VI deposition and ECR is 
independently associated with one-year disease progression in CKD patients.
Methods
Human renal tissue. Previous studies have shown that COL VI is upregulated in fibrosis of the kidney8,9. 
To assess the expression of endotrophin in relationship to COL VI we studied in situ expression in human kidney 
disease. Human renal tissue was obtained from nephrectomized specimens with renal fibrosis from five patients 
with advanced hydronephrosis and/or chronic pyelonephritis as previously described25. Control kidney tissue 
comprised histologically (uninvolved) normal cortex from nephrectomy specimens of five patients with renal cell 
carcinoma or trauma. All human samples were analysed in a retrospective anonymised manner, after the approval 
of the local ethics committee on human research in accordance with the Helsinki Declaration of 1975, as revised 
in 2000 (No. EK244-14).
Assessment of renal tissue. Tissue preparation. Tissue for light microscopy and immunohistochemistry 
was fixed in methyl Carnoy’s solution and embedded in paraffin and 1 mm sections were processed as previously 
described26.
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Masson’s trichrome staining. Sections of human kidney tissue were deparaffinized and rehydrated through absolute 
ethanol, 96% ethanol, 70% ethanol, and finally distilled water. Sections were stained by incubation in Weigert’s iron 
hematoxylin solution for 10 minutes, followed by running warm tap water for 10 minutes, and finally rinsed in distilled 
water. Sections were incubated in Biebrich scarlet-acid fuchsin solution for 10–15 minutes, and subsequently washed in 
distilled water. The sections were incubated in phophomolybdic-phosphotungstic acid solution for 10–15 minutes and 
transferred directly to aniline blue solution and stained for 5–10 minutes. Following a brief rinse in distilled water, sec-
tions were differentiated in 1% acetic acid for 2–5 minutes, washed in distilled water, and quickly dehydrated through 
96% ethanol, absolute ethanol, and finally toluene. Sections were mounted with resinous mounting medium.
Immunohistochemistry. Human kidney tissue were deparaffinized in toluene, rinsed in absolute ethanol and blocked 
with 1.05% H2O2 in absolute ethanol for 20 minutes. Slides were rehydrated by incubation in 96% ethanol, 70% eth-
anol, and finally tap water. The slides were incubated in citrate buffer pH 6.0 overnight at 60 °C to unmask epitopes. 
After incubation the slides were cooled to room temperature and washed in Tris-buffered saline (TBS). To prevent 
non-specific background staining, slides were blocked by incubation with 0.5% casein in TBS. Antibody was diluted in 
TBS as specified: αCOL VI (final concentration 2.0 µg/ml, abcam-6588, abcam), α-endotrophin (final concentration 
2.7 µg/ml, PRO-C6, Nordic Bioscience), irrelevant isotype matched IgG antibody (final concentration 2.0 µg/ml, Code 
X0931, DAKO), and 200 µL was added to each slide followed by overnight incubation at 4 °C. The slides were washed 
in TBS and incubated with the EnVisionTM system HRP kit according to the manufacturer’s instructions (Dako). A 
secondary peroxidase labeled polymer anti-mouse was added for 30 minutes, followed by two washing steps in TBS. 
The tissue was covered with Super EnhancerTM followed by two washing steps in TBS. 3.3′-diaminobenzidine (DAP+) 
substrate chromatogen solution (0.1 nM chromogen in substrate buffer) was added and incubated for 8 minutes at 
room temperature. The colorimetric reaction was stopped by washing in distilled water. The tissue was briefly counter-
stained with Meyer’s hematoxylin and rinsed in tap water. The slides were dehydrated in 96% ethanol, absolute ethanol, 
and finally in toluene. As a negative control, irrelevant isotype matched IgG antibody was used (Code X0931, DAKO) 
in place of the primary antibody; no unspecific staining was observed.
Study subjects. Study description. Four hundred and ninety-nine participants from the Renal Impairment 
in Secondary Care (RIISC) Study (NCT01722383) were included in the study. Detailed methodology of the RIISC 
study has previously been described27. The cohort was designed as a prospective observational cohort study 
designed to identify determinants of adverse outcomes in CKD.
In brief, patients in nephrology clinics in a single renal centre in Birmingham, UK, with non-dialysis high-risk CKD, 
were invited to participate in the study. High-risk CKD was as defined by the UK National Institute for Health and 
Care Excellence 2008 CKD guideline, and comprised one or more of: eGFR <30 mL/min/1.73 m2, or eGFR 30–59 mL/
min/1.73 m2 with a decline of ≥5 mL/min/1.73 m2/year or ≥10 mL/min/1.73 m2/5 years, or a urinary ACR ≥70 mg/
mmol on three occasions28. Patients were excluded if they had received immunosuppression or had started renal 
replacement therapy (RRT). Patients consented to follow-up for 10 years, or either initiation of RRT or death. Ethical 
approval was granted by South Birmingham Local Research Ethics Committee (reference: 10/H1207/6). All patients 
provided written informed consent, and the study was conducted in accordance with the Declaration of Helsinki.
All patients received standard of care during the study. The visits occurred between April 2011 and September 
2014. The last outcome data collection took place on 31st of January 2017 at which point patients, who had not 
reached a study end-point, were censored. Median follow-up time, calculated using the reverse Kaplan-Meier 
method, was 46 months (range 0–72).
Demographic and clinical data. All participants had demographic, clinical, and laboratory data collected 
at recruitment and during follow-up. Comorbidities were recorded and age-adjusted Charlson Comorbidity 
Index (CCI) of each individual was calculated29. Socioeconomic status was assessed using the Index of Multiple 
Deprivation (IMD 2010); lower scores and ranks indicate greater deprivation30. Renal diagnosis was set as ‘Other/
Unknown’, when CKD was due to uncertain aetiology (33.3%), or if it had not been collected (8.6%).
Blood pressure. Blood pressure (BP) was measured using the BpTRU fully automated sphygmomanome-
ter (BpTRU Medical Devices, Coquitlam, BC, Canada), which is obtained by an average of six BP readings at 
one-minute intervals following a five-minute rest period, and is comparable to mean daytime BP from 24-hour 
ambulatory BP monitoring31. Mean arterial pressure (MAP) was calculated with mean systolic blood pressure 
(SBP) and mean diastolic blood pressure (DBP), with the equation: DBP + ((SBP − DBP)/3). Pulse pressure (PP) 
was calculated as the difference between SBP and DBP.
Laboratory Analyses. Processing of samples. Urine samples were processed immediately after collection 
according to pre-defined standard operating procedures and stored at −80 °C until analysis. Biochemistry results 
from the local clinical laboratory were obtained from tests performed in accordance with the current standard 
of care.
Endotrophin. Urinary endotrophin level was measured using a competitive enzyme-linked immunosorbent 
assay (PRO-C6) developed by Nordic Bioscience, Denmark32. The monoclonal antibody employed in the ELISA 
specifically detects the last 10 amino acids of the alpha-3 chain of COL VI (3168′KPGVISVMGT3177′)32. Intra- and 
interassay variation of the assay were below 3.2 and 7.9%, respectively. To account for variations in urine con-
centration, urinary endotrophin was divided by urinary creatinine, and the endotrophin:creatinine ratio (ECR) 
used in analyses.
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Creatinine, urinary ACR, and C-reactive protein. Serum creatinine measurements were performed on a 
Roche Modular Analyser using a blank rated compensated Jaffe reaction, and eGFR was estimated using the 
creatinine-based CKD-EPI equation33. Urinary creatinine was measured using the ADVIA 1800 Chemistry System 
(Bayer HealthCare). Urinary ACR was measured using a Roche Hitachi 702 analyser. C-reactive protein (CRP) was 
measured using the Full Range C-Reactive Protein Kit on a SPATM automated PLUS turbidimeter (The Binding Site 
Group Ltd, UK). The normal range for CRP is between 0.1 and 9 mg/L, with 90 percent below 3 mg/L34.
Statistical analyses. Baseline characteristics are described as frequency and percentage for categorical var-
iables, and as median and interquartile range (IQR) for continuous variables. As there was little missing data, 
complete case analysis was performed, unless otherwise stated.
The primary outcomes comprised: 1) one-year disease progression of chronic kidney disease as defined by a 
decline in eGFR of ≥30% or development of ESRD within 12 months and 2) development of ESRD. Development 
of ESRD was defined as initiation of RRT by either dialysis or renal transplantation and was captured through the 
use of a local database of all patients who initiated RRT. The composite endpoint for one-year disease progression 
was based on a study by Coresh et al. stating that a ≥30% decline in eGFR is associated with a major increased 
relative risk of progressing to ESRD35. To not exclude fast progressing patients from the analysis, we included 
patients that developed ESRD during the first one-year of follow-up in the composite endpoint.
Urinary endotrophin:creatinine ratio (ECR) was analysed per increase in one standard deviation (1 SD) and 
as a categorical variable by dividing the cohort into quartiles (Q1-4). As transformation of ECR did not lead to a 
Gaussian distribution (assessed by a D’Agostino-Pearson omnibus normality test), non-parametric analysis were 
conducted when possible.
Differences between ECR quartiles in respect to baseline characteristics were assessed using a Chi-squared test 
for categorical variables, or the non-parametric Kruskal-Wallis test for continuous variables.
To assess linear association, correlations between ECR and eGFR, one-year relative change in eGFR, and ACR 
were carried out by the non-parametric Spearman’s rank correlation. One-year relative change in eGFR was cal-
culated as the difference between baseline eGFR and eGFR at one year divided by baseline eGFR.
Univariable and multivariable logistic regression analyses were used to analyse the association of urinary 
ECR with one-year disease progression and Cox proportional hazards regression analyses was used to analyse 
the association with development of ESRD. Association of ECR quartiles with one-year disease progression was 
analysed with logistic regression analysis. Associations were adjusted for the main variables used to predict risk 
of disease progression in the clinic namely age, gender, eGFR, and ACR16. To further assess whether other com-
monly obtained patient characteristics affected the association of ECR with outcomes, we adjusted ECR for eGFR 
(Model a), ACR (Model b), eGFR and ACR (Model c), and all variables with a univariable association with ECR 
quartiles (p < 0.1), including gender16 (Model d). Due to missing data for some variables used for adjustment, the 
fully adjusted model only included 406 out of 416 patients (98%) with data available for one-year disease progres-
sion and 484 out of 499 patients (97%) for development of ESRD.
When variables were highly correlated, only the one with the highest association between ECR quartiles 
was included as a candidate variable in model adjustment. As an example, pulse pressure (PP) was selected for 
one-year disease progression and development of ESRD.
Kaplan-Meier survival analysis was performed for quartiles of ECR against development of ESRD, and signif-
icant differences between quartiles was assessed by a Log-rank (Mantel-Cox) test.
All two-tailed p-values below 0.05 were considered significant. Statistical analyses were performed using 
MedCalc (Ostend, Belgium), R (version 3.2.4), or GraphPad Prism (version 7.00).
Net reclassification improvement (NRI) and integrated discrimination improvement (IDI). The 
cfNRI and IDI have been increasingly applied to determine the added value of a biomarker to an existing test 
or model36–39. We used these measures to determine whether the addition of ECR quartiles added incremental 
predictive value to a model containing traditional risk factors for disease progression (age, gender, eGFR, and 
ACR)16. The cfNRI and IDI were calculated in R with the package PredictABEL (version 1.2–2).
It can be interpreted as a measurement of an increase in event rate among those reclassified as having higher 
risk and decrease in event rate among those reclassified as having lower risk.
The cfNRI was calculated as follows. For patients with events, reclassification was the difference between the 
fraction of patients who were reclassified as being at higher risk and the fraction of patients who were reclassified 
to having lower risk:
=−Fraction
number of events with increased predicted risk after addition of ECR
number of events (1)event i
=−Fraction
number of events with decreased predicted risk after addition of ECR
number of events (2)event d
= −− −cfNRI Fraction Fraction (3)event event i event d
For patients without events (nonevent), reclassification was the difference between the fraction of patients who 
were reclassified to lower risk and the fraction of patients who were reclassified to higher risk:
=−Fraction
number of nonevents with decreased predicted risk after addition of ECR
number of nonevents (4)nonevent d
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=−Fraction
number of nonevents with increased predicted risk after addition of ECR
number of nonevents (5)nonevent i
= −− −cfNRI Fraction Fraction (6)nonevent nonevent d nonevent i
The total cfNRI is the sum of correct reclassification among patients with (equation (3)) and without (equation 
(6)) event:
= +cfNRI cfNRI cfNRI (7)total event nonevent
The maximum total cfNRI is 200%, indicating that the predicted risks for all subjects with events are increased, 
and all subjects without events are decreased.
The IDI was calculated as follows.
=+IDI
sum of probability of event after addition of ECR
number of events (8)event ECR
=−IDI
sum of probability of event without addition of ECR
number of events (9)event ECR
= −+ −IDI IDI IDI (10)event event ECR event ECR
=−IDI
sum of probability of event without addition of ECR
number of nonevents (11)nonevent ECR
=+IDI
sum of probability of event after addition of ECR
number of nonevents (12)nonevent ECR
= −− +IDI IDI IDI (13)nonevent nonevent ECR nonevent ECR
The IDI is the sum of correct reclassification among patients with (equation (10)) and without (equation (13)) 
event:
= +IDI IDI IDI (14)event nonevent
Data availability. The datasets generated and analysed during the current study are available from the cor-
responding author on reasonable request.
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